Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Abing­worth, a long-time life sci­ences in­vestor, has an­oth­er $356 mil­lion that it plans to spend co-de­vel­op­ing new med­i­cines through Phase III tri­als and help­ing Big …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER